ESPE Abstracts

Introduction: Debate still exists about the safety of long-term use of prednisone (P) versus hydrocortisone (HC) for treating children with congenital adrenal hyperplasia -21OH D (CAH).Aim: To investigate the linear growth and weigh gain as well as metabolic component in children with CAH who were treated with either HC or P since early infancy for 5 years or more.Methods: Data of ...

Introduction: Prostaglandin E1 (PGE1) is a drug used for ductal patency in cyanotic congenital heart disease, We are reporting an infant with cortical hyperostosis secondary to prolonged use of PGE1, with typical and extensive radiological findings.Case Report: A 2-month-old girl, born at 37 weeks with APGAR scores of 9 & 10 at 1 & 5 min, and birth weight = 2.9 kg. She failed Critical Congenital Heart Defects Scr...

Abstract: Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII). Many risk factors predispose to the occurrence of LD.Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible risk factors of LD in...

Lipohypertrophy (LD) represents the most common cutaneous complication of insulin therapy worldwide. Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII).Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible r...

Introduction: GH stimulates the production of IGF1; however, their metabolic effects are different. GH has lipolytic and anti-insulin actions while IGF1 has insulin-like actions.Objectives: To investigate the value of using the IGF1/GH peak ratio in relation to the anthropometric data of children with growth hormone deficiency (GHD) before and after a year of GH therapy.Patients and Methods...

Introduction: Patients with thalassemia have a high prevalence of malnutrition and low body mass index (BMI), and nutritional intervention studies are scarce.Aim: We performed an electronic search in PubMed, Google Scholar, and Web of Sciences to review nutritional intervention studies and their possible beneficial effect on children and adults with BTM.Results: 17 controlled and/o...

Introduction: Infants with solitary functioning kidney (SFK) may be prone to develop growth problems, which are not well represented in the literature.Objectives: The aim of this study was to evaluate birth size and postnatal growth in infants with SFK.Patients and Methods: We measured the weight, Weight SDS (WAZ), length SDS (LAZ), and weight for length SDS (WLZ) at birth and ever...

Introduction: Accumulating evidence indicates various but significant effects of human breast milk IGF1 (HMIGF1) on infantile linear growth and weight gain.Objectives and Methods: We performed electronic literature systematic review using PubMed, Google Scholar, and Web of Sciences with the aim to provide an update on various effects of HMIGF1 on infantile and childhood growth. We reviewed 12 studies (n= 941 inf...

Introduction: Glycated hemoglobin (HbA1c) is a rough indicator of glycemic control and not useful to evaluate aspects related to acute or daily glycemic changes in diabetic patients. With the emphasis on intensive management of type 1 diabetes (T1DM), data from studies support using Continuous Glucose Monitoring (CGM) to improve glycemic control and reduce glucose variability, which is related to an increase in macro and microvascular complications.<p clas...

we compared gender effect on growth and metabolic control with CAH. Morbidities associated with CAH, including risks of obesity, hypertension, dysglycemia, and dyslipidemia were investigated.Methods: Data from 30 children with CAH were analyzed retrospectively. They received hydrocortisone (n= 11) or prednisolone (n= 19) and fludrocortisone (0.1: 0.15 mg OD) since early infancy. The mean hydrocortisone dose = 22.5 +/- 7...